SET8 inhibition preserves PTEN to attenuate kidney cell apoptosis in cisplatin nephrotoxicity

Xu Yang1, Yingjie Guan1, George Bayliss1

  • 1Department of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, USA.

Cell Death & Disease
|March 31, 2025
PubMed

Insights

SET8 inhibition protects against cisplatin-induced acute kidney injury (AKI) by preserving PTEN, reducing DNA damage, and restoring autophagy. This finding offers a new therapeutic strategy for AKI.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Biochemistry

Background:

  • SET8, a histone methyltransferase, is linked to cancer but its role in acute kidney injury (AKI) is unclear.
  • Aberrant SET8 expression and H4K20me1 are observed in various tumors.

Purpose of the Study:

  • To investigate the role of SET8 in cisplatin-induced AKI.
  • To explore the therapeutic potential of SET8 inhibition in AKI.

Main Methods:

  • Cisplatin-induced AKI model in mice.
  • Administration of SET8 inhibitor UNC0379.
  • In vitro studies using renal proximal tubular epithelial cells (TKPTs).
  • Analysis of renal function, tubular injury, apoptosis, DNA damage response (DDR), and autophagy markers.

Main Results:

  • SET8 and H4K20me1 were upregulated in cisplatin-induced AKI.
  • SET8 inhibition with UNC0379 improved renal function, reduced tubular injury and apoptosis, and preserved PTEN.
  • SET8 inhibition also reduced DDR and restored autophagy.
  • PTEN inhibition exacerbated cisplatin-induced damage, while PTEN overexpression alleviated it. Blocking PTEN diminished the protective effects of SET8 inhibition.

Conclusions:

  • SET8 inhibition protects against cisplatin-induced AKI.
  • The protective mechanism involves PTEN preservation, inhibition of DDR, and restoration of autophagy.
  • Targeting SET8 represents a potential therapeutic strategy for AKI.